Comparative safety of glucose‐lowering medications on depression in adults with type 2 diabetes
Sustained use of GLP-1RA or DPP4i was associated with small, increased risks of incident depression compared with SGLT2i. GLP-1RA use was also associated with increased risk of depression compared to SU. Patients and clinicians may consider these risks along with other potential benefits and risks when initiating glucose-lowering medications.
Authors
- Jasleen Kaur (ORCID: https://orcid.org/0000-0001-7328-7389)
- Rebecca C. Rossom (ORCID: https://orcid.org/0000-0002-9531-914X)
- Holly Finertie (ORCID: https://orcid.org/0000-0003-2732-2694)
- Patrick O’Connor (ORCID: https://orcid.org/0000-0002-8966-9370)
- Tainayah Thomas (ORCID: https://orcid.org/0000-0001-9094-8556)
- Stephanie Ann Hooker (ORCID: https://orcid.org/0000-0003-4222-7046)
- Lisa K. Gilliam (ORCID: https://orcid.org/0000-0001-7054-1409)
- Sarah Krahe Dombrowski (ORCID: https://orcid.org/0009-0003-7020-3794)
- Romain S. Neugebauer (ORCID: https://orcid.org/0000-0002-6085-4564)
- Margaret B Nolan (ORCID: https://orcid.org/0000-0001-5214-3992)
- Andrea E. Cassidy‐bushrow
- Maher Yassin
- Julie A. Schmittdiel (ORCID: https://orcid.org/0000-0001-8995-5345)
- Sharon Lin (ORCID: https://orcid.org/0000-0002-7923-3979)
- RM Bergenstal
- Keanu Izadian
- Jaejin An
- Caryn E. S. Oshiro
Institutions
- Geisinger Medical Center (US)
- Kaiser Permanente (US)
- Henry Ford Health System (US)
- Palo Alto University (US)
- Park Nicollet Clinic (US)
- Colorado Permanente Medical Group (US)
- Geisinger Neuroscience Institute (US)
- HealthPartners (US)
- Geisinger Health System (US)
- Stanford University (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1111/dom.70415
- Primary Topic
- Diabetes Management and Education
- Type
- article
- Field-Weighted Citation Impact
- 0.00